1The FIELD Study Investigators.The need for a large - scale trial of fibrate theapy in diabetes: the rationale anddesign of Lowering the Fenofibrate Intervention and Event in Diabetes (FIELD) study Cardiovascular Diabetology 2004;3:9-20.
2Adkine J.C;,Faulkds D. Micronized fenofibrate: a review of its phar-macologynamic properties and clinical efficacy in the management of hyperlipidemia. Drugs, 1997,54(4):615-633.
1Alagona PJ. Fenofibric acid: A new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia [J]. Vasc Health Risk Manag, 2010 ,25(6) :351 -362.
2Harold EB, Eli MR,James M, et al. The effects of fenofibeic acid alone and with statins on the prevalence of metabolic syndrmne and its diagnostic components in patients with mixed dyslipidemia [J]. Diabetes Care,2010,33(9) :2113 -2116.
3EIisavet M,Anastazia K, Moses SE,et al. Management of dyslipi- demias with fibrates, alone and in combination with statins: role of delayed - release fenofibric acid [ J ]. Vasc Health Risk Man- ag, 2010,6:525-539.
4Lossner A, Banditt P, Troger U. Rapid and simple method for detection of fenofibric acid in human serum by high - performance liquid chromatography[ J]. Pharmazie,2001,56( 1 ) :50 - 51.
5Sunil KD,Manoj ST,Anil KP,et al. Rapid, sensitive and valida- ted ultra - performance liquid chromatography/mass spectrometric method for the determination of fenofibric acid and its application to human pharmacokinetic study [ J ]. E J Chem, 2010,7 ( 1 ) : 25 - 26.
6Straka R J, Burkhardt RT, Fisher JE. Determination of fenofbric acid concentrations by HPLC after anion exchange solid - phase extraction from human serum [ J ]. Ther Drug Monit, 2007, 29 (2) :197 -202.
